Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL321623

CC(=O)C(C)=O.O=C(O)C(O)C(O)C(=O)O.OCC(O)CO

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GBA1 known ✓ P04062 1/20 0.32
TSHR P16473 4/20 0.50
LMNA P02545 2/20 0.45
ALDH1A1 P00352 1/20 0.45
PDE4A P27815 1/20 0.44
OR51E2 Q9H255 1/20 0.42
CYP2C9 P11712 1/20 0.39
THPO P40225 1/20 0.35
TP53 P04637 1/20 0.35
TGFBR1 P36897 1/20 0.33
NFKB1 P19838 1/20 0.33
CYP2C19 P33261 1/20 0.33
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL1933180 0.89 TSHR (0.62) TSHRLMNAALDH1A1PDE4AOR51E2
Cadaverine Tartrate SCHEMBL4214652 0.89 TSHR (0.62) TSHRLMNAALDH1A1PDE4AOR51E2
Cadaverine Tartrate SCHEMBL6560274 0.87 TSHR (0.59) TSHRALDH1A1PDE4AOR51E2CYP2C9
Butanedione SCHEMBL2913079 0.87 LMNA (0.60) TSHRLMNAALDH1A1OR51E2THPO
Cadaverine Tartrate SCHEMBL42202 0.84 TSHR (0.71) TSHRPDE4AOR51E2CYP2C9THPO
Glycerin SCHEMBL23675030 0.81 LMNA (0.53) TSHRLMNAALDH1A1OR51E2TP53
Pyruvate SCHEMBL2052994 0.81 LMNA (0.53) TSHRLMNAALDH1A1PDE4AOR51E2
Pyruvate SCHEMBL30531673 0.81 LMNA (0.53) TSHRLMNAALDH1A1PDE4AOR51E2
Glycerin SCHEMBL27617095 0.81 LMNA (0.53) TSHRLMNAALDH1A1OR51E2TP53
Glycerin SCHEMBL1840579 0.81 LMNA (0.53) TSHRLMNAALDH1A1OR51E2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023190295-A1 LIQUID NUTRITIONAL COMPOSITION AND PACKAGE ニュートリー株式会社 2023-10-05 WO claimed
CN-113875867-A Milk-containing coffee beverage and preparation method thereof 广州市东鹏食品饮料有限公司 2022-01-04 CN claimed
CN-106068080-A Beverage emulsifying agent containing milk composition 理研维他命股份有限公司 2016-11-02 CN claimed
CN-103432091-A Improved-performance tablet and preparation method thereof ZHONG SHUGUANG 2013-12-11 CN claimed
WO-2010112965-A1 ISOLATION COATING OF DICLOFENAC TABLETS ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) 2010-10-07 WO claimed
CN-1891080-A Meat quality-improving agent RIKEN VITAMIN CO (JP) 2007-01-10 CN claimed
US-6818244-B2 LOW-TEMPERATURE, HIGH SPEED REACTION OF A DIACETYLATED TARTARIC ACID ANHYDRIDE MELT AND A MELT OF PARTIAL GLYCERIDES COMPRISING 60-99% MONOGLYCERIDES; EMULSIFIER, DOUGH CONDITIONER FOR FLOUR AND YEAST-LEAVENED BAKERY GOODS QUEST INTERNATIONAL B.V. (NL) 2004-11-16 US claimed
US-6642278-B1 Emulsifiers, dough conditioning, baked goods QUEST INTERNATIONAL B.V. (NL) 2003-11-04 US claimed
US-6635299-B1 Emulsifier for baked goods QUEST INTERNATIONAL B.V. (NL) 2003-10-21 US claimed
US-20030162893-A1 Diacetyl tartaric acid esters of mono- and dig1ycerides based on C12 to C22 fatty acids QUEST INTERNATIONAL B.V. (NL) 2003-08-28 US claimed
EP-1016647-B1 Diacetyl tartaric acid esters of mono- and diglycerides based on C12 to C22 fatty acids QUEST INT (NL) 2003-05-28 EP claimed
WO-2000040542-A1 DIACETYL TARTARIC ACID ESTERS OF MONO- AND DIGLYCERIDES BASED ON C12 TO C22 FATTY ACIDS QUEST INTERNATIONAL B.V. (NL) 2000-07-13 WO claimed
EP-1016647-A1 Diacetyl tartaric acid esters of mono- and diglycerides based on C12 to C22 fatty acids QUEST INTERNATIONAL B.V. (NL) 2000-07-05 EP claimed
WO-2024071966-A1 COMPOSITION FOR DELAYING RANCIDITY OF OIL AND OILS COMPRISING SAME 씨제이제일제당 (주) 2024-04-04 WO disclosed
EP-3589280-B1 FORMULATIONS WITH IMPROVED STABILITY INSPIRNA INC (US) 2024-02-07 EP disclosed
US-20240025870-A1 PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Synaptogenix, Inc. (US) 2024-01-25 US disclosed
WO-2000040542-A1 DIACETYL TARTARIC ACID ESTERS OF MONO- AND DIGLYCERIDES BASED ON C12 TO C22 FATTY ACIDS QUEST INTERNATIONAL B.V. (NL) 2000-07-13 WO disclosed
EP-1016647-A1 Diacetyl tartaric acid esters of mono- and diglycerides based on C12 to C22 fatty acids QUEST INTERNATIONAL B.V. (NL) 2000-07-05 EP disclosed
EP-1016647-A1 Diacetyl tartaric acid esters of mono- and diglycerides based on C12 to C22 fatty acids QUEST INTERNATIONAL B.V. (NL) 2000-07-05 EP disclosed
JP-2000060495-A OIL OR FAT COMPOSITION FOR PROCESSED FISH FOOD AND PROCESSED FISH FOOD RIKEN VITAMIN CO LTD 2000-02-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025870-A1 PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PRKCH, PRKCA, PRKCG GBA1 440/4885TSHR 4318/4885LMNA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.